About Peplin

Peplin focuses on researching, developing and commercializing innovative drugs in medical dermatology.

Peplin trades under the symbol ‘PLI’ on the Australian Securities Exchange (ASX) in the form of Chess Depository Interests (CDIs). The company is headquartered in Emeryville, California with operations in Brisbane, Queensland, Australia and a manufacturing facility in Southport, Queensland.

Our core technology is a novel class of naturally occurring compounds which show significant potential as anti-cancer agents for a wide range of human cancers. The lead compound in this technology, PEP005 (ingenol mebutate), or PEP005, is in Phase III trials for the treatment of actinic keratosis (AK), sometimes known as solar keratosis or sunspots, a common pre-cancerous lesion.

Peplin retains sole rights to develop and market PEP005 and has extensive international patent coverage over its technologies.